Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beta BionicsBBNX -10.15%10 Receivables Turnover is 1.89 as of Jun. 2026. GuruFocus rates BBNX with a GF Score™ of 10/100. The stock has 3 warning signs investors should review. Among 811 Medical Devices & Instruments companies, Beta Bionics ranks better than 82.12% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Beta Bionics's Revenue for the
three
months ended in Jun. 2026 was $32.0 Mil. Beta Bionics's average Accounts Receivable for the
three
months ended in Jun. 2026 was $16.9 Mil.
Hence, Beta Bionics's Receivables Turnover for the
three
months ended in Jun. 2026 was 1.89.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Beta Bionics Receivables Turnover Related Terms
Beta Bionics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Beta Bionics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BBNX vs SSII, SIBN, CBLL: Receivables Turnover Comparison
For the Medical Devices subindustry, Beta Bionics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beta Bionics Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Beta Bionics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Beta Bionics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beta Bionics (BBNX) has a Receivables Turnover of 1.89 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Beta Bionics and its competitors. According to the industry distribution chart, Beta Bionics ranks #145 out of 811 companies in the Medical Devices & Instruments industry, placing it in the top 17.9%.
Is Beta Bionics' Receivables Turnover too high?
Beta Bionics' current Receivables Turnover is 1.89. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. Beta Bionics' value of 1.89 is 65.7% below this industry median. Based on the distribution chart, Beta Bionics ranks #145 out of 811 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Beta Bionics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Beta Bionics' Receivables Turnover compare to SSII and SIBN?
According to the Medical Devices & Instruments industry distribution chart, Beta Bionics ranks #145 out of 811 companies for Receivables Turnover. This places Beta Bionics in the top 18% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.51. Beta Bionics' value of 1.89 is 65.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beta Bionics's current Receivables Turnover of 1.89 is 65.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Beta Bionics and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beta Bionics's current Receivables Turnover is 1.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Bionics stock overvalued right now?
Beta Bionics (BBNX) has a current Receivables Turnover of 1.89. The current Receivables Turnover is 1.89 and 65.7% below the Medical Devices & Instruments industry median of 5.51. Beta Bionics' overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Beta Bionics (BBNX), the current Receivables Turnover is 1.89 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.
10GF Score
Get the complete analysis for BBNX
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BBNX has been successfully added to your 
